TRAFIC

Trial of adjuvant 5FU infusional chemotherapy.

Disease site: Breast cancer

Treatment Modality: Chemotherapy

Status: Closed

Trial details

Randomised trial comparing the efficacy and toxicity of adjuvant chemotherapy (infusional 5FU, epirubicin and cisplatin) with conventional FEC (5FU, epirubicin and cyclophosphamide) in women requiring chemotherapy for poor prognosis breast cancer, irrespective of age and nodal status. 348 patients were randomised from 11 centres between May 1995 and January 2002 to receive either infusional 5-fluorouracil (5-FU) by daily 24 hour continuous infusion via a Hickman line for 18 weeks with epirubicin and cisplatin given as intravenous bolus injections, or 5FU, epirubicin and cyclophosphamide given as intravenous bolus injection. Both regimens were repeated 3 weekly for 6 courses. All patients were offered tamoxifen 20mg orally daily in addition to chemotherapy.

Chief Investigator: Professor I. Smith, Royal Marsden NHS Foundation Trust

ISRCTN: 83324925

Publications and presentations

Sirohi B, A'Hern R, Coombes G, Bliss JM, Hickish T, Perren T, Crawford M, O'Brien M, Iveson T, Ebbs S, Skene A, Laing R, Smith IE. A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Ann. Oncol. 2010;21(8):1623-29

Image of the Institute of Cancer Research building in Sutton
ICR joins £10million AI project to help identify individual cancer risk

22/01/25

Doctors could soon be able to better predict an individual patient’s chances of getting cancer and offer them personalised detection and prevention strategies, thanks to a new research project co-led by scientists at The Institute of Cancer Research, London.
See full story
MR linac machine - cutting edge scanner
Innovative imaging study confirms feasibility of using smaller target areas in radiotherapy for early-stage glottic cancer

21/01/25

Scientists have successfully used real-time MRI to demonstrate that swallowing causes minimal motion of the larynx, known as the voice box, in people undergoing a radiotherapy session for cancer in this part of the body.
See full story